- Home
- AORT
AORT
Artivion Inc.
as 07-11-2025 3:30pm EST
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | KENNESAW |
| Market Cap: | 1.4B | IPO Year: | 1993 |
| Target Price: | $32.40 | AVG Volume (30 days): | 349.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.97 - $32.94 | Next Earning Date: | 08-07-2025 |
| Revenue: | $390,084,000 | Revenue Growth: | 5.94% |
| Revenue Growth (this year): | 12.18% | Revenue Growth (next year): | 10.39% |
Stock Insider Trading Activity of Artivion Inc. (AORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Jun 17 '25 | Sell | $29.50 | 15,000 | $442,500.00 | 65,436 | |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Jun 13 '25 | Sell | $28.44 | 26,132 | $743,131.21 | 65,436 | |
| Holloway Jean F | AORT | SVP, General Counsel | May 27 '25 | Sell | $29.00 | 8,748 | $253,692.00 | 178,510 | |
| SEMEDO ANTHONY B. | AORT | Director | May 23 '25 | Sell | $28.47 | 5,200 | $148,054.40 | 33,059 | |
| Holloway Jean F | AORT | SVP, General Counsel | May 21 '25 | Sell | $29.00 | 9,926 | $287,854.00 | 178,510 | |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | May 9 '25 | Sell | $29.13 | 10,548 | $307,265.35 | 65,436 |
Latest Artivion Inc. News
AORT Breaking Stock News: Dive into AORT Ticker-Specific Updates for Smart Investing
StockStory
15 days ago
The 5 Most Interesting Analyst Questions From Artivion’s Q1 Earnings Call
Argus Research
17 days ago
AORT: Raising target price to $33.00
MT Newswires
24 days ago
Artivion Insider Sold Shares Worth $442,500, According to a Recent SEC Filing
Argus Research
a month ago
AORT: Raising target price to $31.00
PR Newswire
a month ago
Artivion to Participate in Upcoming Investor Conferences
PR Newswire
a month ago
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
Simply Wall St.
2 months ago
Returns On Capital At Artivion (NYSE:AORT) Have Stalled
Argus Research
2 months ago
AORT: Raising target price to $31.00
Compare AORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AORT Artivion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.